Bedaquiline-based all-oral regimen for macrolide-resistant Mycobacterium abscessus pulmonary disease

Int J Tuberc Lung Dis. 2023 Sep 1;27(9):712-713. doi: 10.5588/ijtld.23.0220.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Diarylquinolines / therapeutic use
  • Humans
  • Macrolides* / pharmacology
  • Macrolides* / therapeutic use
  • Mycobacterium abscessus*

Substances

  • bedaquiline
  • Macrolides
  • Diarylquinolines